Ginkgo Bioworks Holdings, Inc. reports developments around cell engineering, autonomous laboratory infrastructure, and contract research services that make biological R&D more programmable. Its updates cover Ginkgo Cloud Lab, Datapoints and Solutions services, Reconfigurable Automation Carts, Catalyst automation software, and AI-enabled workflows for protein engineering, nucleic acid design, cell-free systems, and biological manufacturing.
Company news also includes financial-results presentations, customer and research collaborations, agricultural biotechnology manufacturing work, and capital or governance updates. Following the completed divestiture of its Biosecurity business, recurring coverage centers on Ginkgo's autonomous lab strategy, remote wet-lab access, microbial strain engineering, fermentation processes, and the commercial use of lab-generated biological data.
Ginkgo Bioworks (NYSE: DNA) announced its participation in notable upcoming conferences, enhancing its visibility in the biotech sector. The events include the Truist Securities AI Symposium on March 1, 2022, Cowen 42nd Annual Health Care Conference on March 8, 2022, featuring a fireside chat and a panel discussion, and the HSBC Build with Bio Conference on March 10, 2022. Interested parties can find more information, webcast links, and presentation replays on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) announced its participation in two upcoming conferences. The BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference is scheduled for February 15, 2022, at 10:00 a.m. ET, and the SVB Leerink 11th Annual Global Healthcare Conference will take place on February 18, 2022, at 10:40 a.m. ET. Interested parties can find more details and webcast links on the company's investor relations website.
Ginkgo Bioworks (NYSE: DNA) has acquired Project Beacon COVID-19 LLC, a Boston-based organization focused on enhancing COVID-19 testing accessibility and affordability. This acquisition aims to integrate Project Beacon's assets with Ginkgo's Concentric platform, increasing testing capabilities in Massachusetts and surrounding areas. Ginkgo's Concentric currently serves over 280,000 individuals weekly, having conducted over 3 million tests in the latter half of 2021. The merger is expected to bolster community health initiatives amid rising pandemic concerns.
Ginkgo Bioworks (NYSE: DNA) announced preliminary performance updates for the year ending December 31, 2021. The company expects to meet or exceed its 2021 targets with Biosecurity revenue surpassing its outlook by over 50%. Key highlights include the addition of 30 new cell programs and Foundry revenue exceeding $100 million. Ginkgo reported significant testing volumes through its public health initiative, Concentric, which collected over 280,000 samples weekly. The company will provide audited financial results in March 2022, alongside its outlook for 2022.
Inscripta has announced that Ginkgo Bioworks (NYSE: DNA) has integrated its Onyx™ genome engineering platform into its foundries. This partnership aims to enhance Ginkgo's metabolic and protein engineering workflow efficiency. Initial evaluations indicate that Onyx improved genome editing throughput significantly and reduced design-build-test-learn cycle times by at least 50%. Ginkgo plans to continue investing in innovative technologies that provide faster product development and increased performance in its offerings.
Selecta Biosciences (Nasdaq: SELB) and Ginkgo Bioworks (NYSE: DNA) announced a collaboration on January 10, 2022, to develop next-generation viral capsids for gene therapy. This partnership combines Selecta's ImmTOR platform with Ginkgo's cell programming technology to enhance transduction, tissue tropism, and reduce immunogenicity. Ginkgo will engineer the capsids, while Selecta handles pre-clinical and clinical studies. Financially, Ginkgo could receive up to $1.1 billion in total payments, including milestone payments in Selecta stock and royalties.
Optimvia has partnered with Ginkgo Bioworks (NYSE: DNA) to enhance the manufacturing efficiency of biosynthetic heparin, a critical medicine traditionally sourced from industrial animal agriculture. This collaboration aims to utilize Ginkgo's expertise in cell and enzyme engineering to improve Optimvia's production technology. The initiative seeks to develop non-animal-derived heparin, potentially reducing reliance on animal sources and increasing supply chain resilience for this essential drug.
Ginkgo Bioworks (NYSE: DNA) announced that Co-Founder and CEO Jason Kelly will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 3:45 p.m. Eastern Time. The presentation details, along with a webcast link and replay information, will be available on the company's investor relations website. Ginkgo Bioworks focuses on programming cells for various biotechnology applications, supporting efforts such as COVID-19 testing and vaccine optimization.
Ginkgo Bioworks (NYSE: DNA) has partnered with Benjamin Franklin Institute of Technology (BFIT) to launch an associate degree in biotechnology manufacturing. The program aims to equip graduates for high-demand technician roles in life sciences. Funded by a $100,000 grant from the Kargman Family Foundation, the initiative supports workforce development in Massachusetts, where biotechnology jobs have surged by 67% over the past decade. The program will operate at the Nubian Square Life Science Training Center, enhancing educational access for underrepresented communities.
Ginkgo Bioworks (NYSE: DNA) announced it has detected the BA.3 sublineage of the Omicron variant in North America, sourced from passengers arriving at Newark Liberty International Airport from South Africa. This detection is part of a collaborative COVID-19 surveillance program with the CDC and XpresSpa Group (Nasdaq: XSPA), involving voluntary testing of international travelers. Over 9,000 travelers have participated, with a goal of improving public health responses to emerging variants. The findings highlight the significance of airport-based monitoring in controlling virus spread.